斥资185亿美元牵手石药集团后,阿斯利康每股收益预增双位数

华尔街见闻
Feb 10

2月10日,阿斯利康预计2026年经调整后每股收益将实现两位数百分比增长,符合市场预期。该公司表示,其肿瘤药物业务的强劲销售势头将有效抵消核心糖尿病药物专利到期带来的影响,支撑业绩持续上行。 阿斯利康第四季度利润与收入基本符合预期。公司预计全年收入将维持中高个位数增长,与2025年8%的增幅相近。分析师此前预计,这一预测将为今年晚些时候的业绩上调留出空间。 公司正加速布局减肥药物市场,近日与中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10